1. Home
  2. RYAM vs CLLS Comparison

RYAM vs CLLS Comparison

Compare RYAM & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rayonier Advanced Materials Inc.

RYAM

Rayonier Advanced Materials Inc.

HOLD

Current Price

$5.84

Market Cap

422.1M

ML Signal

HOLD

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$4.84

Market Cap

485.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RYAM
CLLS
Founded
1926
1999
Country
United States
France
Employees
N/A
222
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
422.1M
485.6M
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
RYAM
CLLS
Price
$5.84
$4.84
Analyst Decision
Buy
Strong Buy
Analyst Count
1
2
Target Price
$6.00
$8.50
AVG Volume (30 Days)
544.0K
116.7K
Earning Date
11-04-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,471,356,000.00
$82,551,000.00
Revenue This Year
N/A
$32.58
Revenue Next Year
$6.99
$20.68
P/E Ratio
N/A
N/A
Revenue Growth
N/A
129.04
52 Week Low
$3.35
$1.10
52 Week High
$8.56
$5.48

Technical Indicators

Market Signals
Indicator
RYAM
CLLS
Relative Strength Index (RSI) 41.16 56.30
Support Level $5.59 $4.47
Resistance Level $5.92 $5.45
Average True Range (ATR) 0.22 0.29
MACD -0.02 -0.03
Stochastic Oscillator 27.93 60.39

Price Performance

Historical Comparison
RYAM
CLLS

About RYAM Rayonier Advanced Materials Inc.

Rayonier Advanced Materials Inc is engaged in the production of cellulose specialties, a natural polymer used in the manufacturing of various specialty chemical products, including liquid crystal displays, filters, textiles and performance additives for pharmaceutical, food and other industrial applications. The company's products are used in a variety of applications, including cigarette filters, liquid crystal displays, paints, pharmaceuticals, and food. The company operates in the reportable segments of High Purity Cellulose, Paperboard, and High-Yield Pulp. The key revenue is derived from the High Purity Cellulose segment. Geographically, it derives a majority of its revenue from the United States.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: